SCHEMBL2801643

SCHEMBL2801643

CCOC(=O)c1cnn2c(Nc3cccc(C)c3)c(C(=O)N3CCC4(CC3)COc3cc(F)ccc34)cnc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.42
PDE4B Q07343 2/20 0.39
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
BRAF P15056 8/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 3/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801436 0.93 SMN1; SMN2 (0.39) KDRPDE4BPDE4APDE4CPDE4D
SCHEMBL2803317 0.92 KDR (0.44) KDRPDE4BPDE4APDE4CPDE4D
SCHEMBL2800889 0.92 PDE4B (0.39) KDRPDE4BPDE4APDE4CPDE4D
SCHEMBL2800927 0.91 SMN1; SMN2 (0.39) PDE4BPDE4APDE4CPDE4DSMN1; SMN2
SCHEMBL2801683 0.90 KDM4E (0.36) KDRSMN1; SMN2LMNAMAPTNPSR1
SCHEMBL2802360 0.90 KDM4E (0.36) KDRSMN1; SMN2LMNAMAPTNPSR1
SCHEMBL2801354 0.89 NPC1 (0.38) KDRSMN1; SMN2LMNAMAPTNPSR1
SCHEMBL2799661 0.89 KDM4E (0.38) PDE4BSMN1; SMN2LMNAMAPTNPSR1
SCHEMBL2803189 0.89 PDE4B (0.36) KDRPDE4BPDE4APDE4CPDE4D
SCHEMBL2801628 0.84 HPGD (0.38) SMN1; SMN2LMNAMAPTNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 KDR 3785/4885PDE4B 1603/4885PDE4A 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.